SCHEMBL13879522

SCHEMBL13879522

CC(C)C1NC(=O)N(c2ccc(Cl)cc2)C1=O

nearest known ligand 0.62

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.62
ELANE P08246 2/20 0.43
MGLL Q99685 1/20 0.43
TAS2R8 Q9NYW2 1/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
ALDH1A1 P00352 2/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
SMO Q99835 2/20 0.38
ALOX15 P16050 1/20 0.38
TSHR P16473 1/20 0.38
HSD17B10 Q99714 1/20 0.38
CHRM1 P11229 1/20 0.38
TP53 P04637 1/20 0.37
POLB P06746 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13879428 0.87 LMNA (0.49) LMNAELANEMGLLMEN1KMT2A
SCHEMBL13879463 0.85 LMNA (0.52) LMNATAS2R8MEN1KMT2AALDH1A1
SCHEMBL11866914 0.84 LMNA (0.47) LMNAELANEMGLLMEN1KMT2A
SCHEMBL25069088 0.83 LMNA (0.62) LMNAMGLLTAS2R8MEN1KMT2A
SCHEMBL13879469 0.83 LMNA (0.75) LMNAMGLLTAS2R8MEN1KMT2A
SCHEMBL13879457 0.83 LMNA (0.55) LMNAMGLLMEN1KMT2AALDH1A1
SCHEMBL8722214 0.81 LMNA (0.72) LMNAELANEMGLLMEN1KMT2A
SCHEMBL10744055 0.78 LMNA (0.57) LMNATAS2R8KMT2AALDH1A1CYP1A2
SCHEMBL13879504 0.77 ELANE (0.47) LMNAELANEMGLLMEN1KMT2A
SCHEMBL10743912 0.76 LMNA (0.54) LMNATAS2R8MEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106518772-B Disubstituted 2,4- imidazolinedione of N-1, N-3 and the preparation method and application thereof 山东省农药科学研究院 2019-05-17 CN disclosed
US-20090099186-A1 INHIBITORS OF VIRAL REPLICATION INTERMUNE, INC. 2009-04-16 US disclosed
US-20090099186-A1 INHIBITORS OF VIRAL REPLICATION INTERMUNE, INC. 2009-04-16 US disclosed
WO-2007047146-A2 INHIBITORS OF VIRAL REPLICATION INTERMUNE, INC. (US) 2007-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099186-A1 INHIBITORS OF VIRAL REPLICATION EIF2AK2, HAVCR2, RTF2 LMNA 2024/4885ELANE 364/4885MGLL 2140/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.